A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by BioMarin Pharmaceutical
Translational Research in Oncology
Myriad Genetic Laboratories, Inc.
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
First received: January 9, 2014
Last updated: November 11, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)